ALTEOGEN Inc.
ALTEOGEN is a South Korean biotechnology company developing technologies for biologic medicines and drug delivery. Its research includes enzymes and formulations designed to enable alternative administration of therapeutic antibodies, as well as additional biologic improvement and development approaches. The company works with pharmaceutical partners that may incorporate its platform technologies into therapeutic products. ALTEOGEN is listed on the Korean KOSDAQ market under code 196170 and maintains its corporate operations in South Korea. Official company reports provide the latest clinical, licensing and financial information.
Company at a glance
Corporate information
- Company entity
- ALTEOGEN Inc.
- Headquarters / principal office
- South Korea
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.alteogen.com/en/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
KOSDAQ: 196170
hyaluronidase drug delivery · biologic technologies · biobetters
oncology · biologic drug delivery
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
ALTEOGEN is a South Korean biotechnology company developing technologies for biologic medicines and drug delivery. Its research includes enzymes and formulations designed to enable alternative administration of therapeutic antibodies, as well as additional biologic improvement and development approaches. The company works with pharmaceutical partners that may incorporate its platform technologies into therapeutic products. ALTEOGEN is listed on the Korean KOSDAQ market under code 196170 and maintains its corporate operations in South Korea. Official company reports provide the latest clinical, licensing and financial information.
Business, technology & evidence
- SecuritiesKOSDAQ: 196170
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · ALTEOGEN Inc. ↗ALTEOGEN Inc. ·
- Official issuer and R&D disclosure · ALTEOGEN Inc. ↗ALTEOGEN Inc. ·
- Official issuer and R&D disclosure · ALTEOGEN Inc. ↗ALTEOGEN Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.